On March 9, 2026, Novo Nordisk announced a share repurchase program initiated on February 4, 2026, with a goal of up to DKK 15 billion over 12 months, having already repurchased 5,334,992 shares worth approximately DKK 1.47 billion at an average price of DKK 276.06 per share.